Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption independently of Insulin and Glycemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Growth and Adult Height in Girls With Turner Syndrome Following IGF-1 Titrated Growth Hormone Treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Changes in the homeostatic appetite system after weight loss reflect a normalization toward a lower body weight

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Genetic variation at PPP1R3B increases hepatic CT attenuation and interacts with prandial status on plasma glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Decreased markers of bone turnover in children and adolescents with type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mikkel B Christensen
  • Asger Lund
  • Salvatore Calanna
  • Niklas R Jørgensen
  • Jens J Holst
  • Tina Vilsbøll
  • Filip K Knop
Vis graf over relationer

Context: The gut hormone GIP causes postprandial insulin release and inhibits bone resorption assessed by carboxy-terminal collagen crosslinks (CTX).

Objective: To clarify if GIP affects biomarkers involved in bone homeostasis independently of insulin release and glycemic level.

Design: Randomized, double-blinded, cross-over study with 5 study days.

Patients: Ten lean male C-peptide-negative patients with type 1 diabetes.

Interventions: On 3 matched days with 'low glycemia' (i.e. plasma glucose clamped between 3-7 mmol/L for 120 minutes) we administered (IV) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline); and on 2 matched days with 'high glycemia' (i.e. clamped at 12 mmol/L for 90 minutes) we administered (IV) either GIP (4 pmol/kg/min) or saline.

Main Outcome Measures: CTX, N-terminal propeptide of type 1 procollagen (P1NP), and PTH.

Results: During 'low glycemia': GIP progressively suppressed CTX from baseline by up to 59±18% compared to 24±10% during saline infusion (P<0.0001). Absolute values of P1NP and PTH did not differ between GIP and placebo days. During 'high glycemia': GIP suppressed CTX from baseline by up to 59±19% compared to 7±9% during saline infusion (P<0.0001). P1NP did not differ between GIP and placebo days. GIP suppressed PTH after 60 minutes compared to saline (P<0.01), but this difference disappeared after 90 minutes.

Conclusions: Short term GIP infusions robustly reduces bone resorption independently of endogenous insulin secretion and during both elevated and low plasma glucose levels, but has no effect on P1NP or PTH after 90 minutes.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
Vol/bind103
Udgave nummer1
Sider (fra-til)288-294
Antal sider7
ISSN0021-972X
DOI
StatusUdgivet - 2018

ID: 51975650